Looking for New Physics in B --> K^* \pi and B --> \rho K Decays

B --> K^* \pi and B --> \rho K decays involve the same quark-level processes as B --> \pi K. Analyzing the measurements of the former decays might be able to shed additional light on the new-physics hints in the current B --> \pi K data. We perform fits to B --> K^* \pi and B --> \rho K decays, and find that the data can be accommodated within the standard model. However, this agreement is due principally to the large errors in the data, particularly the CP-violating asymmetries. If the errors on the B --> K^* \pi and B --> \rho K observables can be reduced, one will have a clearer sense of whether new physics is present in these decays.Comment: 12 pages and 6 plots; version to appear in journa

Energy and Charged Particle Flow in 10.8 A GeV/c Au+Au Collisions

Experimental results and a detailed analysis are presented of the transverse energy and charged particle azimuthal distributions measured by the E877 collaboration for different centralities of Au+Au collisions at a beam momentum of 10.8 A GeV/c. The anisotropy of these distributions is studied with respect to the reaction plane reconstructed on an event-by-event basis using the transverse energy distribution measured by calorimeters. Results are corrected for the reaction plane resolution. For semicentral events we observe directed flow signals of up to ten percent. We observe a stronger anisotropy for slow charged particles. For both the charged particle and transverse energy distributions we observe a small but non zero elliptic anisotropy with the major axis pointing into the reaction plane. Combining the information on transverse energy and charged particle flow we obtain information on the flow of nucleons and pions. The data are compared to event generators and the need to introduce a mean field or nucleon-nucleon potential is discussed.Comment: RevTex, 25 pages, 13 figures included as one Postscript file, submitted to Phys. Rev.

Limits on Radio Continuum Emission from a Sample of Candidate Contracting Starless Cores

We used the NRAO Very Large Array to search for 3.6 cm continuum emission from embedded protostars in a sample of 8 nearby ``starless'' cores that show spectroscopic evidence for infalling motions in molecular emission lines. We detect a total of 13 compact sources in the eight observed fields to 5 sigma limiting flux levels of typically 0.09 mJy. None of these sources lie within 1' of the central positions of the cores, and they are all likely background objects. Based on an extrapolation of the empirical correlation between the bolometric luminosity and 3.6 cm luminosity for the youngest protostars, these null-detections place upper limits of ~0.1 L_sun (d/140pc)^2 on the luminosities of protostellar sources embedded within these cores. These limits, together with the extended nature of the inward motions inferred from molecular line mapping (Lee et al. 2001), are inconsistent with the inside-out collapse model of singular isothermal spheres and suggest a less centrally condensed phase of core evolution during the earliest stages of star formation.Comment: Accepted to the Astronomical Journal; 12 pages, 1 figur

Chemoenzymatic Probes for Detecting and Imaging Fucose-α(1-2)-galactose Glycan Biomarkers

The disaccharide motif fucose-α(1-2)-galactose (Fucα(1-2)Gal) is involved in many important physiological processes, such as learning and memory, inflammation, asthma, and tumorigenesis. However, the size and structural complexity of Fucα(1-2)Gal-containing glycans have posed a significant challenge to their detection. We report a new chemoenzymatic strategy for the rapid, sensitive detection of Fucα(1-2)Gal glycans. We demonstrate that the approach is highly selective for the Fucα(1-2)Gal motif, detects a variety of complex glycans and glycoproteins, and can be used to profile the relative abundance of the motif on live cells, discriminating malignant from normal cells. This approach represents a new potential strategy for biomarker detection and expands the technologies available for understanding the roles of this important class of carbohydrates in physiology and disease

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

BackgroundThe large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).MethodsPROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal.ResultsIn 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively.ConclusionsPROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings